öλÔÓéÀֵǼÈë¿ÚÏÂÔØ

µ¼Ê¦ÐÕÃû£º³ÂÕý¸Ú
ÐÔ±ð£º
ÈËÆøÖ¸Êý£º145

ËùÊôԺУ£º´óÁ¬Ò½¿Æ´óѧ
ËùÊôԺϵ£º
Ö°³Æ£º¸±½ÌÊÚ
µ¼Ê¦ÀàÐÍ£ºË¶µ¼
ÕÐÉúöλÔÓéÀֵǼÈë¿ÚÏÂÔØ£º¿Úǻҽѧ
Ñо¿ÁìÓò£º Ö÷ÒªÖÂÁ¦ÓÚRas¼Ò×åµ°°×ÔÚ¿ÚÇ»ò¢Ãæ¶ñÐÔÖ×ÁöµÄ×÷Óü°Æä·Ö×Ó»úÖƵÄÑо¿¡£Ñо¿·½Ïò°üÀ¨£ºRhoA... [Õ¹¿ª]


Ñо¿ÁìÓò£º Ö÷ÒªÖÂÁ¦ÓÚRas¼Ò×åµ°°×ÔÚ¿ÚÇ»ò¢Ãæ¶ñÐÔÖ×ÁöµÄ×÷Óü°Æä·Ö×Ó»úÖƵÄÑо¿¡£Ñо¿·½Ïò°üÀ¨£ºRhoA¡¢RhoB¡¢RhoC¡¢Rac¡¢Cdc42µ°°×ÔÚ¿ÚÇ»ò¢Ãæ¶ñÐÔÖ×ÁöµÄ×÷ÓûúÀíÑо¿¡¢GGTase¡¢Rce1¡¢IcmtøÔÚRasµ°°×ÐÞÊιý³ÌÖеÄ×÷Óᣠ[ÊÕÆð]




ͨѶ·½Ê½ :
µç×ÓÓʼþ£ºchenzhg1973@163.com


¸öÈ˼òÊö :
³ÂÕý¸Ú£¬²©Ê¿£¨²©Ê¿ºó£©£¬¸±½ÌÊÚ¡¢¸±Ö÷ÈÎҽʦ£¬Ë¶Ê¿Éúµ¼Ê¦¡£ÇൺÊаμâÈ˲Å¡¢ÇൺÊÐÒ½ÁÆÎÀÉúÓÅÐãѧ¿Æ´øÍ·ÈË¡£ÏÖÈÎÖ°ÓÚÇൺ´óѧ¸½ÊôÇൺÊÐÊÐÁ¢Ò½Ôº¿ÚǻҽÁÆÖÐÐÄ£¬µ£ÈÎÖÐÐĸ±Ö÷ÈΡ£1999Äê±ÏÒµÓÚɽ¶«Ò½¿Æ´óѧ£¨ÏÖɽ¶«´óѧ£©£¬»ñ¿ÚÇ»ò¢ÃæÍâ¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔØ˶ʿѧλ£»2010Äê±ÏÒµÓÚɽ¶«´óѧ£¬»ñ¿ÚÇ»ò¢ÃæÍâ¿ÆöλÔÓéÀֵǼÈë¿ÚÏÂÔز©Ê¿Ñ§Î»£»2008-2010Ä기Èðµä¸çµÂ±¤´óѧ¹«ÅÉÁôѧ½øÐв©Ê¿ÁªºÏÅàÑø£»2012-2014ÄêÓÚÉϺ£½»Í¨´óѧҽѧԺ¸½ÊôµÚ¾ÅÈËÃñÒ½Ôº²©Ê¿ºóÁ÷¶¯Õ¾´Óʲ©Ê¿ºó¹¤×÷£»Ôø¸°ÃÀ¹ú¡¢º«¹ú½øÐпÚÇ»ò¢ÃæÍâ¿ÆµÄöλÔÓéÀֵǼÈë¿ÚÏÂÔØÅàѵ¡£

¿ÆÑй¤×÷ :
ÔÚÑÐÏîÄ¿
1. ¹ú¼Ò×ÔÈ»¿Æѧ»ù½ðÃæÉÏÏîÄ¿£¬¡°GGTase-I ÔÚK-ras Í»±äÓÕµ¼µÄÉà°©RhoA µ°°×ÐÞÊιý³Ì¼°RhoA-p38MAPK ÐźÅͨ·ÖеÄ×÷Óü°»úÖÆ¡± £¬¿ÎÌ⸺ÔðÈË
2. Öйú²©Ê¿ºó¿Æѧ»ù½ðÃæÉÏ×ÊÖúÏîÄ¿£¬¡°GGTase-IÔÚK-rasÓÕµ¼µÄÉà°©RhoAÐÞÊιý³ÌµÄ×÷Óü°»úÖÆ¡± £¬¿ÎÌ⸺ÔðÈË
3. ɽ¶«Ê¡Ò½Ò©ÎÀÉú¿Æ¼¼·¢Õ¹¼Æ»®ÏîÄ¿ÃæÉÏÏîÄ¿£¬¡°ÆÕÝÁÂå¶ûµÈÄÉÃ×»ºÊÍÒ©ÎïµÄÖƱ¸¼°ÖÎÁÆѪ¹ÜÁöµÄ»úÖÆÑо¿¡± £¬¿ÎÌ⸺ÔðÈË
4. ÇൺÊÐÒ½Ò©¿ÆÑÐÖ¸µ¼¼Æ»®£¬¡°ÁýÐθ´ºÏµ°°×Ö×Áö°ÐÏòÄÉÃ×ÔØÌåµÄ¹¹½¨¼°Æ俹Ö×ÁöµÄ×÷Óá± £¬¿ÎÌ⸺ÔðÈË
5. ÇൺÊÐÎÀÉú¿Æ¼¼¼Æ»®ÏîÄ¿£¬¡°RhoA»ùÒòÓëÉà°©µÄÇÖÏ®ºÍתÒƵĹØϵ¼°Æä»úÖÆÑо¿¡± £¬¿ÎÌ⸺ÔðÈË
6. ÇൺÊÐÎÀÉú¿Æ¼¼¼Æ»®ÏîÄ¿£¬¡°Rho¼Ò×åµ°°×µÄ±í´ïÒÖÖƶԿÚÇ»°©µÄÒÖÖƼ°Ras/MAPK/PKÐźÅͨ·µÄÓ°Ïì»úÖÆ¡± £¬¿ÎÌ⸺ÔðÈË
´ú±íÐÔÎÄÕ£¨*ͨѶ×÷Õߣ©
1. Chen ZG, Zheng JW, Zhang L, Zhu L, Wang YA. A survey on clinical use of propranolol for infantile hemangiomas in mainland China. Int J Clin Exp Med. 20158(2):2138-2146.£¨µÚÒ»×÷Õߣ©
2. Chen ZG, Zheng JW, Yuan ML, Zhang L, Yuan WE. A novel topical nano-propranolol for treatment of infantile hemangiomas. Nanomedicine. 201511(5):1109-1115.£¨µÚÒ»×÷Õߣ©
3. Yang F, Zhang Y, Yuan X, Yu J, Chen S, Chen Z, Guo D, Cai J, Ma N, Guo E. Caries experience and its association with weight status among 8-year-old children in Qingdao, China. J Int Soc Prev Community Dent. 20155(1):52-58.
4. Yan G, Zou R, Chen Z, Fan B, Wang Z, Wang Y, Yin X, Zhang D, Tong L, Yang F, Jiang W, Fu W, Zheng J, Bergo MO, Dalin M, Zheng J, Chen S, Zhou J. Silencing RhoA inhibits migration and invasion through Wnt/¦Â-catenin pathway and growth through cell cycle regulation in human tongue cancer. Acta Biochim Biophys Sin 201446(8):682-690.£¨²¢ÁеÚÒ»×÷Õߣ©
5. Zhou J, Wang L, Chen Z, Qiu J, Dong Q. Giant keratocystic odontogenic tumor of the maxillary sinus and zygoma: A case report. Oncol Lett. 20148(6):2675-2677.
6. Yang F, Ning K, Chang X, Yuan X, Tu Q, Yuan T, Deng Y, Hemme CL, Van Nostrand J, Cui X, He Z, Chen Z, Guo D, Yu J, Zhang Y, Zhou J, Xu J. Saliva microbiota carry caries-specific functional gene signatures. PLoS One. 20149(2):e76458.
7. Zhang D, Chen ZG, Liu SH, Dong ZQ, Dalin M, Bao SS, Hu YW, Wei FC. Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulation beta-catenin. Acta Pharmacol Sin 201334(1):176-184.
8. Zhang L, Mai HM, Zheng J, Zheng JW, Chen ZG, Wang YA, Qin ZP, Li KL, Yuan WE. Preliminary study on plasma RPN concentration of patients with infantile hemangioma treated with propranolol. Int J Clin Exp Med. 20136(5):342-345.
9. Chen Z, Liu S, Sumida T, Sun S, Wei Y, Liu M, Dong Z, Zhang F, Hamakawa H, Wei F. Silencing Id-1 with RNA interference inhibits adenoid cystic carcinoma in mice. J Surg Res **(1):57-66.£¨µÚÒ»×÷Õߣ©
10. Liu M, Sjogren AK, Karisson C, Ibrahim MX, Andersson KM, Olofsson FJ, Wahlstrom AM, Dalin M, Yu H, Chen Z, Yang SH, Young SG, Bergo MO. Targeting the protein prenyltransferases efficiency reduces tumor development in mice with K-RAS-induced lung cancer. Proc Natl Acad Sci U S A **(14):6471-6476.
11. Dong Z, Liu S, Zhou C, Sumida T, Hamakawa H, Chen Z, Liu P, Wei F. Overexpression of Id-1 is associated with tumor angiogenesis and poor clinical outcome in oral squamous cell carcinoma. Oral Oncol 201046(3):154-157.
12. ÑϹúöΣ¬·®±ø£¬×ÞÈÙº££¬ÕŽ¡£¬ËïÏþ·å£¬Í¯ÀÚ£¬ÍõÆæÃñ£¬º«½ðºê£¬Â³Ðñ·É£¬ÍõÓ¨£¬ÖÜÔª£¬ºÎ×ÚÐù£¬ÁÎÞÈÏ裬ÀîÄþ£¬²ÜÀÙ£¬³ÂÕý¸Ú*£®³ÁĬRhoA»ùÒò¶ÔÉàÁÛ״ϸ°û°©Ï¸°ûÔöÖ³µÄÓ°Ï죮»ªÎ÷¿ÚǻҽѧÔÓÖ¾£¬2016ÄêµÚ34¾íµÚ6ÆÚ£¬620-625.
13. ³ÂÕý¸Ú£¬ÌÆÓÀƽ£¬Í¯ÀÚ£¬ÍõÓ¨£¬ÖÜÔª£¬ÍõÆæÃñ£¬º«½ðºê£¬ºÎ×ÚÐù£¬ÁÎÞÈÏ裬·®±ø£¬×ÞÈÙº££¬ÕŽ¡£¬ËïÏþ·å£¬ÑϹúöΣ®ÌåÍâRNA¸ÉÈÅRhoA»ùÒò¶ÔÉ఩ϸ°ûÇÖÏ®µÄÓ°Ï죮»ªÎ÷¿ÚǻҽѧÔÓÖ¾£¬2016ÄêµÚ34¾íµÚ2ÆÚ£¬183-188.£¨µÚÒ»×÷Õߣ©
14. ÍõÓ¨£¬º«½ðºê£¬ÍõÆæÃñ£¬Â³Ðñ·É£¬ÖÜÔª£¬²ÜÀÙ£¬ÀîÄþ£¬ºÎ×ÚÐù£¬ÁÎÞÈÏ裬ͯÀÚ£¬³ÂÕý¸Ú*£®µ¥µÙëñµº×´°êÅäºÏÁ½°êÊõÖÎÁÆëñÁѵÄÊÖÊõ¹Û²ìºÍÆÀ¼Û£®ÖйúÒ½ÁÆÃÀÈÝ£¬2016ÄêµÚ3ÆÚ£¬34-36.
15. º«½ðºê£¬ÍõÓ¨£¬ÍõÆæÃñ£¬Â³Ðñ·É£¬ÖÜÔª£¬²ÜÀÙ£¬ÀîÄþ£¬ºÎ×ÚÐù£¬ÁÎÞÈÏ裬ͯÀÚ£¬³ÂÕý¸Ú*£®Millard´½ÁÑÐÞ¸´ÊõЧ¹ûµÄÁÙ´²ÆÀ¼Û£¬ÖйúÒ½ÁÆÃÀÈÝ£¬2016ÄêµÚ6¾íµÚ9ÆÚ£¬50-53.
16. º«½ðºê£¬ÍõÆæÃñ£¬ÍõÓ¨£¬Â³Ðñ·É£¬ÖÜÔª£¬²ÜÀÙ£¬ÀîÄþ£¬ºÎ×ÚÐù£¬ÁÎÞÈÏ裬ͯÀÚ£¬³ÂÕý¸Ú*£®¶ùͯҹĥÑÀÓë×èÈûÐÔ˯ÃߺôÎüÔÝÍ£×ÛºÏÕ÷µÄÏà¹ØÐÔ̽ÌÖ£¬ÁÙ´²Ò½Ò©ÎÄÏ×ÔÓÖ¾£¬2016ÄêµÚ3¾íµÚ36ÆÚ£¬7128-7129.
17. Ö£¼Ò࣬ÕÅÁ裬³ÂÕý¸Ú*£®Âö¹ÜÒì³£µÄISSVAзÖÀ࣮Öйú¿ÚÇ»ò¢ÃæÍâ¿ÆÔÓÖ¾£¬2015ÄêµÚ13¾íµÚ5ÆÚ£¬385-388.
18. Ö£¼Ò࣬ÕÅÁ裬³ÂÕý¸Ú*. Ó¤Ó׶ùѪ¹ÜÁöµÄÕï¶ÏÓëÖÎÁÆ. Öйú¿ÚÇ»ò¢ÃæÍâ¿ÆÔÓÖ¾£¬2015ÄêµÚ13¾íµÚ4ÆÚ£¬289-296.
19. ÕÅ´ºÑÞ£¬ÓÚ½­²¨£¬ÁõÎÄ£¬ËÎÁᣬ¹ù´ó࣬Áõ¼ÒÄþ£¬Ô¬Ïþ£¬³ÂÕý¸Ú*£®ÇáÐͶàÐÎÐÔºì°ßµÄ¿ÚÇ»¾Ö²¿¼¤ËØÖÎÁÆ£®ÖйúÁÙ´²Ò½ÉúÔÓÖ¾£¬2015ÄêµÚ43¾íµÚ10ÆÚ£¬64-65.
20. ÌÕÔÈÑÅ£¬Ö£¼Í࣬ÑϹúöΣ¬¸¶ÎÄʤ£¬ÍõÓ¨£¬Öܽ¨»ª£¬ÓÚ½­²¨£¬Ñî·¼£¬¹ù´óΰ£¬Í¯ÀÚ£¬³ÂÕý¸Ú*£®Ç°±ÛÓÎÀëƤ°êÐÞ¸´Éà°©Êõºó×é֯ȱËðµÄÓïÒôЧ¹ûÆÀ¼Û£®ÖйúÁÙ´²Ò½ÉúÔÓÖ¾£¬2014ÄêµÚ42¾íµÚ11ÆÚ£¬80-81,84.
21. ÁõÎľý£¬Í¯ÀÚ£¬Áõ¸£Ñ§£¬Ã·èò±ò£¬ÀîÃô£¬Çñ½Ü£¬Íõ¹ú»ª£¬ÚùêÝƼ£¬³ÂÕý¸Ú*£®¶ùͯ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£µÍͨÆø×ÛºÏÕ÷ÉÏÆøµÀ½á¹¹µÄMRIÑо¿·ÖÎö£®É½¶«´óѧ¶ú±ÇºíÑÛѧ±¨£¬2013ÄêµÚ27¾íµÚ5ÆÚ£¬47-51.
22. ÁõÎľý£¬Áõ¸£Ñ§£¬Í¯ÀÚ£¬Ã·èò±ò£¬Íõ¹ú»ª£¬ÚùêÝƼ£¬ÀîÃô£¬Çñ½Ü£¬³ÂÕý¸Ú*£®¶ùͯ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£µÍͨÆø×ÛºÏÕ÷ÉÏÆøµÀ½á¹¹µÄÓ°Ïñѧ²âÁ¿·ÖÎö£®ÖйúÁÙ´²Ò½Éú£¬2013ÄêµÚ41¾íµÚ9ÆÚ£¬53-55.
23. ÔøԶʤ£¬Â¬ÖÒÁÖ£¬»Ææµ¾ý£¬³ÂÕý¸Ú*£®FurlowÊõʽ¼°¸ÄÁ¼À¼Ê½ÐÞ¸´Ç³II¶ÈëñÁѵÄÁÙ´²Ñо¿£®¹ã¶«ÑÀ²¡·ÀÖΣ¬2013ÄêµÚ21¾íµÚ4ÆÚ£¬193-195.
24. Ö£¼Ò࣬ÕÅÁ裬³ÂÕý¸Ú£®ÆÕÝÁÂå¶ûÖÎÁÆÓ¤Ó׶ùѪ¹ÜÁöר¼Ò¹²Ê¶£®Öйú¿ÚÇ»ò¢ÃæÍâ¿ÆÔÓÖ¾£¬2013ÄêµÚ11¾íµÚ2ÆÚ£¬161-164.
25. ³ÂÕý¸Ú£¬¶­×÷Ç࣬ÕŶ«£¬Öܳɾü£¬ËïÉÆÕ䣬ÁõÉÙ»ª£¬Îº·î²Å£®ÂÌÉ«Ó«¹âµ°°×תȾ±ê¼ÇÏÙÑùÄÒÐÔ°©Éú³¤µÄÂãÊóÄ£ÐÍ£®»ªÎ÷¿ÚǻҽѧÔÓÖ¾£¬2011ÄêµÚ29¾íµÚ4ÆÚ£¬424-428.£¨µÚÒ»×÷Õߣ©
26. ¹ù¼ÍÃ÷£¬³ÂÕý¸Ú£¬Çñ½¨ÖÒ£¬Öܽ¨»ª£¬Íõ¿ËÌΣ¬¶­×÷Ç࣮¾­¿ÚÇ»¸ÄÁ¼À©´ó¹ÎÖÎÊõÖÎÁÆÏÂò¢¹Ç¾ÞÐͱÚÐÔ³ÉÓÔϸ°ûÁö£®Öйú¿ÚÇ»ò¢ÃæÍâ¿ÆÔÓÖ¾£¬2011ÄêµÚ9¾íµÚ2ÆÚ£¬151-156.£¨²¢ÁеÚÒ»×÷Õߣ©